BOULDER – Corden Pharma Colorado Inc. expects to see “synergies” in connection with parent company International Chemical Investors Group’s recent plan to buy peptide manufacturer Peptisyntha, a spokesman said.

In addition, a Corden Pharma global operations representative is visiting local facilities at 2075 55th St. this week, said Brad DeHoff, technical development and process director at the plant. DeHoff declined to give specific details of the possible “synergies.”

The Boulder plant also was mentioned in a press release from ICIG in conjunction with the purchase announcement last week. Frankfurt, Germany-based ICIG did not disclose the price the company plans to pay for Peptisyntha, which is headquartered in Brussels, Belgium. The sale is expected to close in October, DeHoff said.

Along with Peptisyntha, the Boulder plant and a plant in Liestal, Switzerland, offer “development capacities, Christian Ewers, chief operating officer of CordenPharma’s active pharmaceutical ingredients division, said in the press release.

With the purchase, Ewers said, “we will be in an excellent position to offer customers the full range of peptide synthesis strategies and services.”

Research on peptides, or chains of amino acids, to create drug candidates to treat a variety of diseases, has been on the rise locally and around the globe in recent years.

Corden Pharma acquired the Boulder facility in 2011, when it purchased Boulder-based Roche Colorado Corp. Roche was a subsidiary of Switzerland-based F. Hoffmann-La Roche AG. Corden Pharma Colorado employed about 200 people locally at the time, the company said.

ICIG is privately owned. Its companies employ more than 3,500 people and operate 19 manufacturing facilities in Europe and the United States with sales of about $1.06 billion, according to the press release.